{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T22:22:43Z","timestamp":1769293363169,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background\/objectives<\/jats:title>\n                    <jats:p>The initial visual acuity (VA) prior to treatment initiation can significantly influence long-term visual outcomes. The current analysis aimed to examine change in VA by baseline vision categories and their effects on time spent within visual change categories in patients with diabetic macular oedema (DMO) who underwent treatment with the intravitreal fluocinolone acetonide (FAc) implant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Subjects\/methods<\/jats:title>\n                    <jats:p>This was a post-hoc analysis of the IRISS-Registry Data. Time-in-range (TIR) was calculated based on three VA letter-score-thresholds: \u226570, \u226565, and \u226560 ETDRS letters after treatment initiation. TIR was stratified by baseline VA in three groups: 0\u201333, 34\u201368, and 69\u2013100 letters. The primary outcome was the mean TIR for the \u226570 letters threshold (equivalent to 6\/12 in Snellen).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 671 eyes from 542 patients were included. VA improved significantly in all VA swimlane groups, with 84.8%, 71.7%, and 60.0% of eyes in the 0\u201333, 34\u201368, and 69\u2013100 baseline VA categories, respectively, showing maintained or improved VA at 36 months (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0367). The mean TIR for the \u226570 letter threshold was significantly longer in the 69\u2013100 letters subgroup (892.7\u2009\u00b1\u2009413.4 days) compared to the 34\u201368 (648.4\u2009\u00b1\u2009366.4 days) and 0\u201333 (251.3\u2009\u00b1\u2009175.9 days) subgroups (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). No significant differences in TIR were observed based on the duration of DMO or the number of previous anti-angiogenic injections.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Eyes with better initial VA maintained functionally better visual acuity for longer following FAc implant treatment. TIR emerged as a potentially clinically relevant endpoint for evaluating long-term treatment outcomes in DMO, offering a broader perspective than traditional VA measures.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-025-04102-8","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T07:27:33Z","timestamp":1764746853000},"page":"252-259","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of baseline visual acuity, time-in-range and early treatment on functional outcomes in DMO: insights from the IRISS outcomes"],"prefix":"10.1038","volume":"40","author":[{"given":"Igor","family":"Kozak","sequence":"first","affiliation":[]},{"given":"Ramin","family":"Khoramnia","sequence":"additional","affiliation":[]},{"given":"Simon R.","family":"Taylor","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2606-3734","authenticated-orcid":false,"given":"Usha","family":"Chakravarthy","sequence":"additional","affiliation":[]},{"name":"on behalf of the ILUVIEN Registry Safety Study (IRISS) Investigators Group","sequence":"additional","affiliation":[]},{"given":"Robin","family":"Hamilton","sequence":"additional","affiliation":[]},{"given":"Usha","family":"Chakravarthy","sequence":"additional","affiliation":[]},{"given":"Guzaliya","family":"Safiullina","sequence":"additional","affiliation":[]},{"given":"Geeta","family":"Menon","sequence":"additional","affiliation":[]},{"given":"Ramesh","family":"Sivaraj","sequence":"additional","affiliation":[]},{"given":"Haralabos","family":"Eleftheriadis","sequence":"additional","affiliation":[]},{"given":"Simon R.","family":"Taylor","sequence":"additional","affiliation":[]},{"given":"Saad","family":"Younis","sequence":"additional","affiliation":[]},{"given":"Konstantinos","family":"Balaskas","sequence":"additional","affiliation":[]},{"given":"Vasant","family":"Raman","sequence":"additional","affiliation":[]},{"given":"Fahd","family":"Quhill","sequence":"additional","affiliation":[]},{"given":"Bushra","family":"Mushtaq","sequence":"additional","affiliation":[]},{"given":"Nicholas","family":"Glover","sequence":"additional","affiliation":[]},{"given":"Ben","family":"Burton","sequence":"additional","affiliation":[]},{"given":"David","family":"Steel","sequence":"additional","affiliation":[]},{"given":"Salim","family":"Natha","sequence":"additional","affiliation":[]},{"given":"Somnath","family":"Banerjee","sequence":"additional","affiliation":[]},{"given":"Deepthi","family":"Seneviratne","sequence":"additional","affiliation":[]},{"given":"Nishal","family":"Patel","sequence":"additional","affiliation":[]},{"given":"Spyridon","family":"Mourtzoukos","sequence":"additional","affiliation":[]},{"given":"Riaz","family":"Asaria","sequence":"additional","affiliation":[]},{"given":"Ajay","family":"Bhatnagar","sequence":"additional","affiliation":[]},{"given":"Rehna","family":"Khan","sequence":"additional","affiliation":[]},{"given":"Ahmed","family":"Kamal","sequence":"additional","affiliation":[]},{"given":"Clare","family":"Bailey","sequence":"additional","affiliation":[]},{"given":"Louise","family":"Downey","sequence":"additional","affiliation":[]},{"given":"Anil","family":"Kumar","sequence":"additional","affiliation":[]},{"given":"Gon\u00e7alo","family":"Almeida","sequence":"additional","affiliation":[]},{"given":"Patrick","family":"Richardson","sequence":"additional","affiliation":[]},{"given":"Hadi","family":"Zambarakji","sequence":"additional","affiliation":[]},{"given":"Colin","family":"Jones","sequence":"additional","affiliation":[]},{"given":"Katrin","family":"Lorenz","sequence":"additional","affiliation":[]},{"given":"Karl U.","family":"Bartz-Schmidt","sequence":"additional","affiliation":[]},{"given":"Frank","family":"Holz","sequence":"additional","affiliation":[]},{"given":"Lars","family":"Wagenfeld","sequence":"additional","affiliation":[]},{"given":"Peter","family":"Wiedemann","sequence":"additional","affiliation":[]},{"given":"Rainer","family":"Guthoff","sequence":"additional","affiliation":[]},{"given":"Manfred","family":"Tetz","sequence":"additional","affiliation":[]},{"given":"Gerd U.","family":"Auffarth","sequence":"additional","affiliation":[]},{"given":"Christian","family":"Ksinsik","sequence":"additional","affiliation":[]},{"given":"Frank","family":"Koch","sequence":"additional","affiliation":[]},{"given":"Helmut","family":"Sachs","sequence":"additional","affiliation":[]},{"given":"Dirk","family":"Sandner","sequence":"additional","affiliation":[]},{"given":"Berthold","family":"Seitz","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o","family":"Figueira","sequence":"additional","affiliation":[]},{"given":"\u00c2ngela","family":"Carneiro","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9","family":"Henriques","sequence":"additional","affiliation":[]},{"given":"Rufino","family":"Silva","sequence":"additional","affiliation":[]},{"given":"Miguel","family":"Amaro","sequence":"additional","affiliation":[]},{"given":"Angelina","family":"Meireles","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o Paulo","family":"Castro Sousa","sequence":"additional","affiliation":[]},{"given":"Ant\u00f3nio","family":"Rodrigues","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Carvalho","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"4102_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.preteyeres.2017.10.006","volume":"63","author":"A Daruich","year":"2018","unstructured":"Daruich A, Matet A, Moulin A, Kowalczuk L, Nicolas M, Sellam A, et al. Mechanisms of macular edema: Beyond the surface. Prog Retin Eye Res. 2018;63:20\u201368.","journal-title":"Prog Retin Eye Res"},{"key":"4102_CR2","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1038\/eye.2017.53","volume":"31","author":"R Gale","year":"2017","unstructured":"Gale R, Scanlon PH, Evans M, Ghanchi F, Yang Y, Silvestri G, et al. Action on diabetic macular oedema: achieving optimal patient management in treating visual impairment due to diabetic eye disease. Eye. 2017;31:S1\u2013S20.","journal-title":"Eye"},{"key":"4102_CR3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000458539","volume":"237","author":"U Schmidt-Erfurth","year":"2017","unstructured":"Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237:185\u2013222.","journal-title":"Ophthalmologica"},{"key":"4102_CR4","doi-asserted-by":"publisher","first-page":"3362","DOI":"10.3390\/cells11213362","volume":"11","author":"J Zhang","year":"2022","unstructured":"Zhang J, Zhang J, Zhang C, Zhang J, Gu L, Luo D, et al. Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications. Cells. 2022;11:3362. https:\/\/doi.org\/10.3390\/cells11213362.","journal-title":"Cells"},{"key":"4102_CR5","doi-asserted-by":"publisher","first-page":"9591","DOI":"10.3390\/ijms24119591","volume":"24","author":"T Tatsumi","year":"2023","unstructured":"Tatsumi T. Current Treatments for Diabetic Macular Edema. Int J Mol Sci. 2023;24:9591 https:\/\/doi.org\/10.3390\/ijms24119591.","journal-title":"Int J Mol Sci"},{"key":"4102_CR6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ajo.2016.09.012","volume":"172","author":"VH Gonzalez","year":"2016","unstructured":"Gonzalez VH, Campbell J, Holekamp NM, Kiss S, Loewenstein A, Augustin AJ, et al. Early and Long-Term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data. Am J Ophthalmol. 2016;172:72\u201379.","journal-title":"Am J Ophthalmol"},{"key":"4102_CR7","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1136\/bjophthalmol-2020-315933","volume":"105","author":"TA Ciulla","year":"2021","unstructured":"Ciulla TA, Pollack JS, Williams DF. Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28,658 patient eyes. Br J Ophthalmol. 2021;105:216\u201321.","journal-title":"Br J Ophthalmol"},{"key":"4102_CR8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/IAE.0000000000001555","volume":"38","author":"U Chakravarthy","year":"2018","unstructured":"Chakravarthy U, Yang Y, Lotery A, Ghanchi F, Bailey C, Holz FG, et al. Clinical evidence of the multifactorial nature of diabetic macular edema. Retina. 2018;38:343\u201351.","journal-title":"Retina"},{"key":"4102_CR9","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1001\/jamaophthalmol.2015.5346","volume":"134","author":"SB Bressler","year":"2016","unstructured":"Bressler SB, Ayala AR, Bressler NM, Melia M, Qin H, Ferris FL, et al. Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment. JAMA Ophthalmol. 2016;134:278\u201385.","journal-title":"JAMA Ophthalmol"},{"key":"4102_CR10","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/s41433-019-0522-z","volume":"34","author":"SR Sadda","year":"2020","unstructured":"Sadda SR, Campbell J, Dugel PU, Holekamp NM, Kiss S, Loewenstein A, et al. Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I data. Eye. 2020;34:480\u201390.","journal-title":"Eye"},{"key":"4102_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-023-00463-y","volume":"9","author":"SP Chitturi","year":"2023","unstructured":"Chitturi SP, Venkatesh R, Mangla R, Parmar Y, Sangoram R, Yadav NK, et al. Real-world treatment outcomes after delayed intRavitreal therapy in center-involving diabetic macular edema - RETORT study. Int J Retin Vitreous. 2023;9:22. https:\/\/doi.org\/10.1186\/s40942-023-00463-y. Mar 30.","journal-title":"Int J Retin Vitreous"},{"key":"4102_CR12","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41433-023-02667-w","volume":"38","author":"C Rennie","year":"2024","unstructured":"Rennie C, Lotery A, Payne J, Singh M, Ghanchi F. Suboptimal outcomes and treatment burden of anti-vascular endothelial growth factor treatment for diabetic macular oedema in phakic patients. Eye. 2024;38:215\u201323.","journal-title":"Eye"},{"key":"4102_CR13","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.oret.2020.05.018","volume":"4","author":"AX Chen","year":"2020","unstructured":"Chen AX, Greenlee TE, Conti TF, Briskin IN, Singh RP. Fluctuations in Macular Thickness in Patients with Retinal Vein Occlusion Treated with Anti-Vascular Endothelial Growth Factor Agents. Ophthalmol Retin. 2020;4:1158\u201369.","journal-title":"Ophthalmol Retin"},{"key":"4102_CR14","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/s41433-021-01672-1","volume":"36","author":"VY Wang","year":"2022","unstructured":"Wang VY, Kuo BL, Chen AX, Wang K, Greenlee TE, Conti TF, et al. Fluctuations in macular thickness in patients with diabetic macular oedema treated with anti-vascular endothelial growth factor agents. Eye. 2022;36:1461\u20137.","journal-title":"Eye"},{"key":"4102_CR15","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1097\/IAE.0000000000004213","volume":"44","author":"H Torres-Villaros","year":"2024","unstructured":"Torres-Villaros H, Timoumi R, Fajnkuchen F, Klokner A, Giocanti-Aur\u00e9gan A. Macular thickness fluctuations and visual acuity outcomes after intravitreal dexamethasone implant for diabetic macular edema. Retina. 2024;44:1937\u201344.","journal-title":"Retina"},{"key":"4102_CR16","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.ophtha.2012.09.014","volume":"120","author":"PA Campochiaro","year":"2013","unstructured":"Campochiaro PA, Nguyen QD, Hafiz G, Bloom S, Brown DM, Busquets M, et al. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology. 2013;120:583\u20137.","journal-title":"Ophthalmology"},{"key":"4102_CR17","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/j.ophtha.2012.04.030","volume":"119","author":"PA Campochiaro","year":"2012","unstructured":"Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119:2125\u201332.","journal-title":"Ophthalmology"},{"key":"4102_CR18","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1016\/j.ophtha.2014.04.019","volume":"121","author":"J Cunha-Vaz","year":"2014","unstructured":"Cunha-Vaz J, Ashton P, Iezzi R, Campochiaro P, Dugel PU, Holz FG, et al. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema. Ophthalmology. 2014;121:1892\u2013903.","journal-title":"Ophthalmology"},{"key":"4102_CR19","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/eye.2015.98","volume":"29","author":"Y Yang","year":"2015","unstructured":"Yang Y, Bailey C, Holz FG, Eter N, Weber M, Baker C, et al. FAME study group. Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants. Eye. 2015;29:1173\u201380.","journal-title":"Eye"},{"key":"4102_CR20","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1136\/bjophthalmol-2018-312284","volume":"103","author":"U Chakravarthy","year":"2019","unstructured":"Chakravarthy U, Taylor SR, Koch FHJ, Castro de Sousa JP, Bailey C. ILUVIEN Registry Safety Study (IRISS) Investigators Group. Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries. Br J Ophthalmol. 2019;103:1072\u20137.","journal-title":"Br J Ophthalmol"},{"key":"4102_CR21","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1136\/bjo-2022-321415","volume":"107","author":"R Khoramnia","year":"2023","unstructured":"Khoramnia R, Peto T, Koch F, Taylor SR, Castro de Sousa JP, Hill L, et al. Safety and effectiveness of the fluocinolone acetonide intravitreal implant (ILUVIEN): 3-year results from the European IRISS registry study. Br J Ophthalmol. 2023;107:1502\u20138.","journal-title":"Br J Ophthalmol"},{"key":"4102_CR22","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.2337\/dci19-0028","volume":"42","author":"T Battelino","year":"2019","unstructured":"Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019;42:1593\u2013603.","journal-title":"Diabetes Care"},{"key":"4102_CR23","doi-asserted-by":"crossref","unstructured":"Kozak I, Do DV, Lai H, Ogidigben MJ, L\u00f3pez FJ. Time-in-Range analysis of responses after intravitreal dexamethasone therapy in eyes with diabetic macular edema. Ophthalmol Sci. 2025;5:100833.","DOI":"10.1016\/j.xops.2025.100833"},{"key":"4102_CR24","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1016\/j.ophtha.2007.06.047","volume":"114","author":"RW Beck","year":"2007","unstructured":"Beck RW, Maguire MG, Bressler NM, Glassman AR, Lindblad AS, Ferris FL. Visual acuity as an outcome measure in clinical trials of retinal diseases. Ophthalmology. 2007;114:1804\u20139.","journal-title":"Ophthalmology"},{"key":"4102_CR25","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.ophtha.2007.12.004","volume":"115","author":"DJ Browning","year":"2008","unstructured":"Browning DJ, Glassman AR, Aiello LP, Bressler NM, Bressler SB, Danis RP, et al. Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. Ophthalmology. 2008;115:1366\u20131371.e1.","journal-title":"Ophthalmology"},{"key":"4102_CR26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40123-018-0155-5","volume":"8","author":"A Eaton","year":"2019","unstructured":"Eaton A, Koh SS, Jimenez J, Riemann CD. The USER Study: A Chart Review of Patients Receiving a 0.2 \u00b5g\/day Fluocinolone Acetonide Implant for Diabetic Macular Edema. Ophthalmol Ther. 2019;8:51\u201362.","journal-title":"Ophthalmol Ther"},{"key":"4102_CR27","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1177\/1120672119834474","volume":"30","author":"AJ Augustin","year":"2020","unstructured":"Augustin AJ, Bopp S, Fechner M, Holz F, Sandner D, Winkgen AM, et al. Three-year results from the Retro-IDEAL study: Real-world data from diabetic macular edema (DMO) patients treated with ILUVIEN\u00ae (0.19\u2009mg fluocinolone acetonide implant). Eur J Ophthalmol. 2020;30:382\u201391.","journal-title":"Eur J Ophthalmol"},{"key":"4102_CR28","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1136\/bjophthalmol-2020-315984","volume":"105","author":"SE Mansour","year":"2021","unstructured":"Mansour SE, Kiernan DF, Roth DB, Eichenbaum D, Holekamp NM, Kaba S, et al. Two-year interim safety results of the 0.2 \u00b5g\/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study. Br J Ophthalmol. 2021;105:414\u20139.","journal-title":"Br J Ophthalmol"},{"key":"4102_CR29","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1038\/s41433-021-01542-w","volume":"36","author":"C Bailey","year":"2022","unstructured":"Bailey C, Chakravarthy U, Lotery A, Menon G, Talks J, Medisoft Audit Group. Extended real-world experience with the ILUVIEN\u00ae (fluocinolone acetonide) implant in the United Kingdom: 3-year results from the Medisoft\u00ae audit study. Eye. 2022;36:1012\u20138.","journal-title":"Eye"},{"key":"4102_CR30","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3390\/pharmaceutics14040723","volume":"14","author":"T Mathis","year":"2022","unstructured":"Mathis T, Papegaey M, Ricard C, Rezkallah A, Matonti F, Sudhalkar A, et al. Efficacy and Safety of Intravitreal Fluocinolone Acetonide Implant for Chronic Diabetic Macular Edema Previously Treated in Real-Life Practice: The REALFAc Study. Pharmaceutics. 2022;14:723. https:\/\/doi.org\/10.3390\/pharmaceutics14040723.","journal-title":"Pharmaceutics"},{"key":"4102_CR31","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ophtha.2022.01.015","volume":"129","author":"MA Singer","year":"2022","unstructured":"Singer MA, Sheth V, Mansour SE, Coughlin B, Gonzalez VH. Three-Year Safety and Efficacy of the 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: The PALADIN Study. Ophthalmology. 2022;129:605\u201313.","journal-title":"Ophthalmology"},{"key":"4102_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-84362-y","volume":"11","author":"M Fallico","year":"2021","unstructured":"Fallico M, Maugeri A, Lotery A, Longo A, Bonfiglio V, Russo A, et al. Fluocinolone acetonide vitreous insert for chronic diabetic macular oedema: a systematic review with meta-analysis of real-world experience. Sci Rep. 2021;11:4800. https:\/\/doi.org\/10.1038\/s41598-021-84362-y.","journal-title":"Sci Rep"},{"key":"4102_CR33","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1038\/s41433-023-02507-x","volume":"37","author":"I Kozak","year":"2023","unstructured":"Kozak I, Pearce I, Cheung CMG, Machewitz T, Lambrou GN, Molina D, et al. Visual acuity time in range: a novel concept to describe consistency in treatment response in diabetic macular oedema. Eye. 2023;37:3367\u201375.","journal-title":"Eye"},{"key":"4102_CR34","doi-asserted-by":"publisher","first-page":"ix","DOI":"10.1016\/j.ajo.2023.08.013","volume":"256","author":"I Kozak","year":"2023","unstructured":"Kozak I, Stewart MW. The \u201cTime in Range\u201d Concept in Ophthalmology. Am J Ophthalmol. 2023;256:ix\u2013x. https:\/\/doi.org\/10.1016\/j.ajo.2023.08.013.","journal-title":"Am J Ophthalmol"},{"key":"4102_CR35","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1001\/jama.2019.5790","volume":"321","author":"CW Baker","year":"2019","unstructured":"Baker CW, Glassman AR, Beaulieu WT, Antoszyk AN, Browning DJ, Chalam KV, et al. Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial. JAMA. 2019;321:1880\u201394.","journal-title":"JAMA"},{"key":"4102_CR36","unstructured":"Do D, PANORAMA Study Investigators. Visual impact of vision threatening complications and center-involved diabetic macular oedema in patients with non-proliferative diabetic retinopathy: Results from the PANORAMA trial. Retina Society Annual Meeting 2021, presented Wednesday, September 29, 2021. Available in: https:\/\/www.retinasociety.org\/content\/documents\/program_final_round3.pdf Last accessed April 14, 2025."}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04102-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04102-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04102-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T11:37:55Z","timestamp":1769168275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04102-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4102"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-04102-8","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr Igor Kozak reports no conflict of interest. Dr Ramin Khoramnia resports grants from Chengdu Kanghong; grants, personal fees, and non-financial support from Alimera\u00a0Sciences, Bayer, Novartis and Roche, personal fees and non-financial support from Allergan, Heidelberg Engineering, Outlook Therapeutics and Zeiss outside the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study involves human participants and was approved by UK Health and Social Care Research Ethics Committee 2 (14\/NI\/0002). Portugal Comissao de Etica para a Saude da AIBILI (N\/A), Comissoes de Etica para a Saude Instituto de Retina de Lisboa (N\/A), Comissao de Etica para a Investigacao Clinica (2014-EO-03), Comissoes de Etica para a Saude Hospital Vila Franca de Xira (N\/A), Comissoes de Etica para a Saude Centro Hospitalar do Porto (2015.130; 117-DEFI\/ 107-CES), Comissoes de Etica para a Saude Centro Hospitalar de Leiria (N\/A), Comissoes de Etica para a Saude Centro Hospitalar de Setubal (0015\/2016F), Comissoes de Etica para a Saude Centro Hospitalar de Lisboa Ocidental, Entidades Publicas Empresarial (N\/A), Comissao de Etica da Unidade de Saude Local Matosinhos (36\/CE\/JAS). Germany Ethikkommission Landes\u04d3rztekammer Rheinland-Pfalz (837.501.13; 9186-F), Ethikkommission Universit\u04d3ts Klinikum Tubingen (088\/2014BO2), Ethikkommission Rheinische Friedrich-Wilhelms- Universit\u04d3t (044\/14), Ethikkommission der Arztekammer Hamburg (N\/A), Ethik kommission Universit\u04d3t Leipzig (N\/A), Ethikkommission Universit\u04d3t Dusseldorf (4585), Ethikkommission der Arztekammer Berlin (N\/A), Ethikkommission Heidelberg (S-058\/ 2014). Participants gave informed consent to participate in the study before taking part.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Consent obtained directly from patient(s).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}}]}}